2',6'-Dimethylphenoxyacetyl: A new achiral high affinity P3-P2 ligand for peptidomimetic-based HIV protease inhibitors

Journal of Medicinal Chemistry

Volumn 43, Issue 6, 2000, Pages 1094-1108

  Beaulieu, Pierre L ^a   Anderson, Paul C ^a   Cameron, Dale R ^a   Croteau, Gilbert ^a   Gorys, Vida ^a   Grand Maître, Chantal ^a   Lamarre, Daniel ^a   Liard, Francine ^a   Paris, William ^a   Plamondon, Louis ^a,c   Soucy, François ^a,d   Thibeault, Diane ^a   Wernic, Dominik ^a   Yoakim, Christiane ^a   Pav, Susan ^b   Tong, Liang ^b,e  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c Biomedical Research Center   (United States)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

^e Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PALINAVIR; PROTEINASE INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; BIOAVAILABILITY; CRYSTAL STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIGAND BINDING; MOLECULAR MODEL; RECEPTOR AFFINITY; VIRUS REPLICATION; X RAY CRYSTALLOGRAPHY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CELL LINE; CRYSTALLOGRAPHY, X-RAY; DRUG EVALUATION, PRECLINICAL; HIV PROTEASE INHIBITORS; HIV-1; LIGANDS; MODELS, MOLECULAR; PYRIDINES; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 0034704737     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990336n     Document Type: Article

References (50)

1. (a) Khol, N. E.; Emini, E. A.; Schleif, W. A.; Davis, L. J.; Heimbach, J. C.; Dixon, R. A. F.; Scolnick, E. M.; Sigal, I. S. Active HIV-1 protease is required for viral infectivity. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 4686-4690.
2. (b) Kramer, R. A. et al. Science 1986, 231, 1580-1584.
3. Kempf, D. J.; Sham, H. L. HIV protease inhibitors. Curr. Pharm. Des. 1996, 2, 225-246.
4. (a) Deeks, S. G.; Smith, M.; Holodniy, M.; Kahn, J. O. HIV-1 protease inhibitors. A review for clinicians. J. Am. Med. Assoc. 1997, 277, 145-153.
5. (b) Flexner, C. HIV-protease inhibitors. N. Engl. J. Med. 1998, 338, 1281-1292.
6. (c) Glaxo Wellcome/Vertex' Agenerase wins accelerated FDA approval. Pharma Marketletter 1999, April 26, 18.
7. (a) Lamarre, D.; Croteau, G.; Wardrop, E.; Bourgon, L.; Thibeault, D.; Clouette, C.; Vaillancourt, M.; Cohen, E.; Pargellis, C.; Yoakim, C.; Anderson, P. C. Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease. Antimicrob. Agents Chemother. 1997, 965-971.
8. (b) Gorys, V.; Soucy, F.; Yoakim, C.; Beaulieu, P. L. Substituted pyrrolidine derivatives as HIV protease inhibitors. U.S. Patent 5 552 405, 1996.
9. (c) Anderson, P. C.; Soucy, F.; Yoakim. C.; Lavallée, P.; Beaulieu, P. L. Substituted pipecolinic acid derivatives as HIV protease inhibitors. U.S. Patent 5 545 640, 1997, and 5 807 870, 1998
10. Tong, L.; Pav, S.; Mui, S.; Lamarre, D.; Yoakim, C.; Beaulieu, P.; Anderson, P. C. Crystal structures of HIV-2 protease in complex with inhibitors containing the hydroxyethylamine dipeptide isostere. Structure 1995, 3, 33-40.
11. Navia, M. A. Chaturvedi, P. R. Design principles for orally bioavailable drugs. Drug Discovery Today 1996, 1, 179-189.
12. Kempf, D. J. Progress in the discovery of orally bioavailable inhibitors of HIV protease. Perspect. Drug Discovery Des. 1995, 2, 427-436.
13. 2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation. J. Med. Chem. 1996, 39, 3278-3290 and references therein.
14. (b) Kim, E. E.; Baker, C. T.; Dwyer, M. D.; Murcko, M. A.; Rao, B. G.; Tung, R. D.; Navia, M. A. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J. Am. Chem. Soc. 1995, 117, 1181-1182.
15. 2 ligand for symmetry-based HIV protease inhibitors. Bioorg. Med. Chem. Lett. 1996, 8, 2847-2852.
16. 2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere. Bioorg. Med. Chem. Lett. 1998, 8, 687-690.
17. 3 ligands. J. Med. Chem. 1996, 39, 96-108.
18. (a) Kaldor, S.; Kalish, V. J.; Davies, II, J. F.; Shetty, B. V.; Fritz, J. E.; Appelt, K.; Burgess, J. A.; Campanale, K. M.; Chirgadze, N. Y.; Clawson, D. K.; Dressman, B. A.; Hatch, S. D.; Khalil, D. A.; Kosa, M. B.; Lubbehusen, P. P.; Muesing, M. A.; Patick, A. K.; Reich, S. H.; Su, K. S.; Tatlock, J. H. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 1997, 40, 3979-3985.
19. (b) Shetty, B. V.; Kosa, M. B.; Khalil, D. A.; Webber, S. Antimicrobial Agents Chemotherapy 1996, 40, 110-114.
20. (c) Munroe, J. E.; Hornback, W. J.; Campbell, J. B.; Ouellette, M. A.; Hatch, S. D.; Muesing, M. A.; Wiskerchen, M.; Baxter, A. J.; Su, K.; Campanale, K. LY316340: a potent HIV-1 protease inhibitor containing a high affinity octahydrothienopyridine hydroxyethylamine isostere. Bioorg. Med. Chem. Lett. 1995, 5, 2885-2890.
21. (d) Randad, R. S.; Lubkowska, L.; Bhat, T. N.; Munshi, S.; Gulnik, S. V.; Yu, B.; Erickson, J. W. Symmetry-based HIV protease inhibitors: rational design of 2-methylbenzamides as novel P2/P2′ ligands. Bioorg. Med. Chem. Lett. 1995, 5, 1707-1712.
22. Moss, N.; Beaulieu, P.; Duceppe, J.-S.; Ferland, J.-M.; Gauthier, J.; Ghiro, E.; Goulet, S.; Guse, I.; Llinàs-Brunet, M.; Plante, R.; Plamondon, L.; Wernic, D.; Déziel, R. Ureido-based peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase: an investigation of inhibitor bioactive conformation. J. Med. Chem. 1996, 39, 2178-2187 and references therein.
23. Roberts, N. A.; Martin, J. A.; Kinchington, D.; Broadhurst, A. V.; Craig, J. C.; Duncan, I. B.; Galpin, S. A.; Handa, B. K.; Kay, J.; Khrön, A.; Lambert, R. W.; Merrett, J. H.; Mills, J. S.; Parkes, K. E. B.; Redshaw, S.; Ritchie, A. J.; Taylor, D. L.; Thomas, G. J.; Machin, P. J. Rational design of peptide-based HIV proteinase inhibitors. Science 1990, 248, 358-361.
24. (a) Sham, H. L.; Kempf, D. J.; Molla, A.; Marsh, K. C.; Kumar, G. D.; Chen, C.-M.; Kati, W.; Stewart, K.; Lal, R.; Hsu, A.; Betebenner, D.; Korneyeva, M.; Vasavanonda, S.; McDonald, E.; Saldivar, A.; Wideburg, N.; Chen, X.; Niu, P.; Park, C.; Jayanti, V.; Grabowski, B.; Granneman, G. R.; Sun, E.; Japour, A. J.; Leonard, J. M.; Plattner, J. J.; Norbeck, D. W. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 1998, 42, 3218-3224.
25. (b) Mimoto, T.; Kato, R.; Takaku, H.; Nojima, S.; Terashima, K.; Misawa, S.; Fukazawa, T.; Ueno, T.; Sato, H.; Shintani, M.; Kiso, Y.; Hayashi, H. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine. J. Med. Chem. 1999, 42, 1789-1802.
26. i = 6 and 23 pM, respectively), we assume similar binding modes with the enzymes.
27. (a) Stewart, J. J. P. MOPAC: a semiempirical molecular orbital program. J. Comput.-Aid. Mol. Des. 1990, 4, 1-105.
28. (b) Cramer, C. J.; Truhlar, D. G. PM3-SM3: a general parametrization for including aqueous solvation effects in the PM3 molecular orbital model. J. Comput. Chem. 1992, 13, 1089-1097.
29. (a) Liard, F.; Ghiro, E.; Paris, W.; Yoakim, C. Determination of the HIV protease inhibitor BILA 2185 BS in rat plasma by liquid-liquid extraction and high performance liquid chromatography photodiode array detector. J. Pharm. Biomed. Anal. 1995, 14, 151-154.
30. (b) Liard, F.; Jaramillo, J.; Paris, W.; Yoakim, C. Pharmacokinetic aspects of palinavir, an HIV protease inhibitor, in Sprague-Dawley rats. J. Pharm. Sc. 1998, 87, 782-785.
31. Pargellis, C. A.; Morelock, M. M.; Graham, E. T.; Kinkade, P.; Pav, S.; Lubbe, K.; Lamarre, D.; Anderson, P. C. Determination of kinetic rate constants for the binding of inhibitors to HIV-1 protease and for the association and dissociation of active homodimer. Biochemistry 1994, 33, 12527-12534.
32. i, allowing for the 266-fold discrepancy observed between these values.
33. Beaulieu, P. L.; Wernic, D. Abraham, N.; Anderson, P. C.; Bogri, T.; Bousquet, Y.; Croteau, G.; Guse, I.; Lamarre, D.; Liard. F.; Paris, W.; Thibeault, D.; Pav, S.; Tong, L. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere. J. Med. Chem. 1997, 40, 2164-2176.
34. (a) Unpublished results.
35. (b) Doyon, L.; Croteau, G.; Thibeault, D.; Poulin, F.; Pilote, L.; Lamarre, D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 1996, 70, 3763-3769.
36. (c) Croteau, G.; Doyon, L.; Thibeault, D.; McKercher, G.; Pilote, L.; Lamarre, D. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J. Virol. 1997, 71, 1089-1096.
37. Beaulieu, P. L.; Lavallée, P.; Abraham, A.; Anderson, P. C.; Boucher, C.; Bousquet, Y.; Duceppe, J.-S.; Gillard, J.; Gorys, V.; Grand-Maître, C.; Grenier, L.; Guindon, Y.; Guse, I.; Plamondon, L.; Soucy, F.; Valois, S.; Wernic, D.; Yoakim, C. Practical, stereoselective synthesis of palinavir, a potent HIV protease inhibitor. J. Org. Chem. 1997, 62, 3440-3448.
38. Knorr, R.; Trzeciak, A.; Bannwarth, W.; Gillessen, D. New coupling reagents in peptide chemistry. Tetrahedron Lett. 1989, 30, 1927-1930.
39. Moreau, C.; Rouessac, F. Le comportement thermique de trois alcénylphénols. Les m-et p-hydroxyphényl-5 pentène-1 et l'o-méthyl m-hydroxyphényl-5 pentène-1. Bull. Soc. Chim. Fr. 1973, 3427-3432.
40. Bodansky, M. In Principles of Peptide Synthesis; Springler-Verlag: New York, 1984.
41. (a) Gillard, J.; Abraham, A.; Anderson, P. C.; Beaulieu, P. L.; Bogri, T.; Bousquet, Y.; Grenier, L.; Guse, I.; Lavallée, P. Preparation of (2S,4R)-4-hydroxypipecolic acid and derivatives. J. Org. Chem. 1996, 61, 2226-2231.
42. (b) Bousquet, Y.; Anderson, P. C.; Bogri, T.; Duceppe, J.-S.; Grenier, L.; Guse, I. Preparation of enantiopure 4-oxygenated pipecolic acid derivatives. Tetrahedron 1997, 53, 15671-15680.
43. (a) Beaulieu, P. L.; Wernic, D.; Duceppe, J.-S.; Guindon, Y. Large scale preparation of (2S,3S)-N-boc-3-amino-1,2-epoxy-4-phenylbutane: a key building block for HIV-protease inhibitors. Tetrahedron Lett. 1995, 36, 3317-3320.
44. (b) Beaulieu, P. L.; Wernic, D. Preparation of aminoalkyl chlorohydrin hydrochlorides: key building blocks for hydroxyethylamine-based HIV protease inhibitors. J. Org. Chem. 1996, 61, 3635-3645.
45. Houpis, I. N.; Molina, A.; Reamer, R. A.; Lynch, J. E.; Volante, R. P.; Reider, P. J. Towards the synthesis of HIV-protease inhibitors. Synthesis of optically pure 3-carboxyl-decahydroisoquinolines. Tetrahedron Lett. 1993, 34, 2593-2596.
46. (a) Betagari, R.; Hopkins, J. L.; Thibeault, D.; Emmanuel, M. J.; Chow, G. C.; Skoog, M. T.; deDreu, P.; Cohen, K. A. Rapid, sensitive and efficient HPLC assays for HIV-1 proteinase. Biochem. Biophys. Methods 1993, 27, 191-197.
47. (b) Pav, S.; Lubbe, K.; Dô, F.; Lamarre, D.; Pargellis, C.; Tong, L. Microtube batch protein crystallization: applications to human immunodeficiency virus type 2 (HIV-2) protease and human renin. Proteins: Struct., Funct., Genet. 1994, 20, 98-102.
48. (a) Fischer, A.; King, M. J.; Robinson, F. P. Inductive substituent constants from dissociation of methyl-substituted 4-picolinium ions. Can. J. Chem. 1978, 56, 3072-3077.
49. (b) Fischer, A.; King, M. J.; Robinson, F. P. Inductive substituent constants from dissociation of methyl-substituted 3-picolinium ions. Can. J. Chem. 1978, 56, 3068-3071.
50. (c) Fischer, A.; King, M. J.; Robinson, F. P. Inductive substituent constants from dissociation of methyl-substituted 2-picolinium ions. Can. J. Chem. 1978, 56, 3059-3067.